Evidence map›Paper›PMID 37589773›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Measuring disability in multiple sclerosis: the WHODAS 2.0.

Carolyn A Young, David J Rog, Basil Sharrack, Cris Constantinescu, Seema Kalra, Tim Harrower, Dawn Langdon, Alan Tennant, Roger J Mills, Trajectories of Outcome in Neurological Conditions (MS) Study Group

Abstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Linking Personality Traits to Disability Progression in Multiple Sclerosis: A Longitudinal Analysis.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carolyn A YoungWalton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, L9 7LJ, UK. Carolyn.young11@nhs.net.ORCID http://orcid.org/0000-0003-1745-7720
David J RogNorthern Care Alliance NHS Trust, Salford, UK.
Basil SharrackAcademic Department of Neurology, University of Sheffield, Sheffield, UK.
Cris ConstantinescuUniversity of Nottingham, Nottingham, UK.
Seema KalraUniversity Hospital of North Midlands NHS Trust, Stoke-on-Trent, UK.
Tim HarrowerUniversity of Exeter Medical School, Exeter, UK.
Dawn LangdonRoyal Holloway, University of London, Egham, Surrey, UK.
Alan TennantLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Roger J MillsWalton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, L9 7LJ, UK.
Trajectories of Outcome in Neurological Conditions (MS) Study Group

Funding

Multiple Sclerosis Society C009-16.1
6 · The paper itself

Abstract

introductionReliable measurement of disability in multiple sclerosis (MS) using a comprehensive, patient self-reported scale, such as the World Health Organization Disability Assessment Schedule (WHODAS) 2.0, would be of clinical and research benefit.

methodsIn the Trajectories of Outcome in Neurological Conditions-MS study, WHODAS 2.0 (WHODAS-36 items for working, WHODAS-32 items if not working, WHODAS-12 items short-form) was examined using Rasch analysis in 5809 people with MS.

resultsThe 36- and 32-item parallel forms, and the cognitive and physical domains, showed reliability consistent with individual or group use. The 12-item short-form is valid for group use only. Interval level measurement for parametric statistics can be derived from all three scales which showed medium to strong effect sizes for discrimination across characteristics such as age, subtype, and disease duration. Smallest detectable difference for each scale was < 6 on the standardised metric of 0-100 so < 6% of the total range. There was no substantial differential item functioning (DIF) by age, gender, education, working full/part-time, or disease duration; the finding of no DIF for time or sample supports the use of WHODAS 2.0 for longitudinal studies, with the 36- and 32-item versions and the physical and cognitive domains valid for individual patient follow-up.

conclusionsDisability in MS can be comprehensively measured at interval level by the WHODAS 2.0, and validly monitored over time. Routine use of this self-reported measure in clinical and research practice would give valuable information on the trajectories of disability of individuals and groups.

Indexed as

Multiple SclerosisPersons with DisabilitiesDisability EvaluationHumansPsychometricsQuality of LifeReproducibility of ResultsWorld Health OrganizationAssessmentDisabilityMultiple sclerosisPatient reported outcome measureRaschTrajectories of Outcome in Neurological Conditions (TONiC)World Health Organization Disability Assessment Schedule 2.0

Identifiers

PMID37589773
PMCPMC10522513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.